We recently compiled a list of the 7 Blue Chip Stocks with Low PE Ratios. In this article, we are going to take a look at ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

We recently compiled a list of 10 Most Promising Long-Term Stocks According to Hedge Funds. In this article, we will look at ...

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level. Read why I ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Summit Therapeutics (NASDAQ: SMMT). This California-based biotech is developing a cancer medicine that has produced excellent clinical trial results in one area where Keytruda is the leader. Summit ...

We recently compiled a list titled 7 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. In this article, we will ...

We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Merck ... of prescription drugs or other necessary ...

Keytruda’s current list price is about $11,564 per ... Big Pharma companies such as Merck and BMS have avoided the drastic PD-1 drug price reductions in China’s national reimbursement scheme ...